CVSA Covista Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Provider of postsecondary education with focus on medical and healthcare programs
• • Emphasis on regulatory compliance risks impacting Title IV funding and clinical placement limitations for medical schools
• • Strategic focus on expansion via campus openings, new programs, and acquisitions despite regulatory and integration challenges
• • Goodwill and intangible assets of $961.3M and $765.5M respectively, representing 63% of total assets as of June 30, 2025
• • Authorized $150M share repurchase program through 2028 with full authorization still available as of June 2025

Risk Factors

• • Regulatory risk from U.S. Department of Education (ED) Borrower Defense to Repayment rules affecting Title IV loan obligations recovery
• • Geopolitical exposure to U.S. federal and state investigations, risking Title IV program eligibility restrictions across multiple institutions
• • Operational risk from potential loss of accreditation or degree-granting authority due to regulatory non-compliance outcomes
• • Competitive threat from adverse publicity and regulatory scrutiny impacting student enrollment relative to other proprietary education providers
• • Financial risk from potential large monetary judgments or fines exceeding existing insurance coverage, impacting cash flows and results

Management Discussion & Analysis

• • No revenue or profit figures disclosed in the MD&A section
• • Key risk: potential fines, debt discharge liabilities, or suspension from Title IV programs due to "substantial misrepresentation" claims
• • Best/worst segment details not provided; focus on risk of institutional non-compliance with ED regulatory standards
• • No cash flow, capital allocation, buybacks, dividends, or capex information given
• • Forward-looking risk: enforcement actions or restrictions by ED may materially affect operations, financial condition, and cash flows

What are the latest CVSA SEC filings in 2026?

Covista Inc. (CVSA) has filed a 10-K annual report on August 7, 2025, a 10-Q quarterly report on May 7, 2026, an 8-K current report on July 28, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did CVSA file its most recent 10-K annual report?

Covista Inc. (CVSA) filed its most recent 10-K annual report on August 7, 2025. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view CVSA 10-Q quarterly reports?

Covista Inc. (CVSA)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every CVSA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has CVSA filed recently?

Covista Inc. (CVSA)'s most recent 8-K was filed on July 28, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find CVSA insider trading activity (Form 4)?

SignalX aggregates every CVSA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does CVSA file with the SEC?

Covista Inc. (CVSA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CVSA filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Covista Inc. (CVSA).

What is CVSA's SEC CIK number?

Covista Inc. (CVSA)'s SEC CIK (Central Index Key) number is 730464. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 730464 to look up all CVSA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find CVSA return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Covista Inc. (CVSA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.